Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adoptive SARS-CoV-2 Specific T Cell Transfer in Patients at Risk for Severe COVID-19 (ACT-COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04762186
Recruitment Status : Not yet recruiting
First Posted : February 21, 2021
Last Update Posted : February 21, 2021
Sponsor:
Collaborators:
ZKS Köln
MMH Institute for Transfusion Medicine
Miltenyi Biomedicine GmbH
Information provided by (Responsible Party):
Universitätsklinikum Köln

Brief Summary:
Monocentric open phase I (dose escalation component), followed by a multi-center, randomized, phase II component benchmarking IMP+SoC against SoC

Condition or disease Intervention/treatment Phase
Moderate COVID-19-infection Drug: IMP 1,000 plus SoC Drug: IMP 5,000 plus SoC Drug: IMP RP2D plus SoC Drug: SoC Phase 1 Phase 2

Detailed Description:

The clinical trial will consist of a phase I and a phase II part. The main trial objective in the phase I part is to determine the recommended phase II dose (RP2D) of adoptive SARS-CoV 2-specific T cells by evaluation of safety and tolerability.

In the phase II part, the primary objective is to gain first data on efficacy of adaptive therapy with adoptive SARS-CoV-2-specific T cells. This will be a randomized, prospective feasibility trial.

All study patients at WHO ordinal scale ≥ 5 will receive the current SoC for treatment of Covid-19. Currently this is remdesivir (loading dose 200mg i.v. on day 1, 100mg maintenance dose day two to five (up to day 10), dexamethasone 6mg once daily p.o. or i.v. up to day 10 and a subcutaneous thromboembolism prophylaxis with low molecular-weight heparin. Due to the dynamic of the ongoing COVID-19 pandemic, SoC treatments are underlying rapid changes and are continuously developed. Therefore, SoC treatment as defined at the time of respective IMP dosing, will be administered.

The adoptive SARS-CoV-2 specific T cells are suspended and formulated in 50 ml of platelet additive solution and will be administered intravenously within 15 min to 30 min.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 51 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

The clinical trial will consist of a phase I and a phase II part. The main trial objective in the phase I part is to determine the recommended phase II dose (RP2D) of SARS-CoV-2-specific T cells by evaluation of safety and tolerability.

In the phase II part the primary objective is to gain first data on efficacy of adoptive therapy with SARS-CoV-2-specific T cells. This will be a randomized, prospective feasibility trial.

Masking: None (Open Label)
Masking Description:

During the dose-escalation phase I of this clinical trial, the study participants and the study team are aware of the treatment as this is an open label trial.

During phase II both study participants and the study team are aware of the treatment as this again is an open label trial.

Primary Purpose: Treatment
Official Title: A Randomized Phase I/II Trial to Analyse Safety and Efficacy of Adoptive SARS-CoV-2 Specific T Cell Transfer in Patients at Risk for Severe COVID-19
Estimated Study Start Date : April 1, 2021
Estimated Primary Completion Date : September 1, 2022
Estimated Study Completion Date : December 1, 2022

Arm Intervention/treatment
Experimental: Phase I dose level 1
Dose level one consists of 3 study patients receiving 1,000 adoptive SARS-CoV-2 specific T cells (IMP) per kg BW. If the first recipient does not experience a DLT associated with the dose level one therapeutic cells within 28 days, the second and third patient will receive 1.000 SARS-CoV-2 adoptive SARS-CoV-2 specific T cells per kg BW. If patient second and third do not experience a DLT within 14 days after treatment, the dose level two will be initiated.
Drug: IMP 1,000 plus SoC

Intravenous administration of 1,000 adoptive SARS-CoV-2 specific T cells (IMP) per kg BW.

The adoptive SARS-CoV-2 specific T cells are suspended and formulated in 50 ml of platelet additive solution and will be administered intravenously within 15 min to 30 min.

All study patients at WHO Ordinal Scale ≥ 5 will receive the current SoC for treatment of COVID-19. Currently this is remdesivir (loading dose 200 mg i.v. on day 1, 100 mg maintenance dose day two to five (up to day 10)) - only WHO Ordinal Scale 5, dexamethasone 6 mg once daily p.o. or i.v. up to day 10 and a subcutaneous thromboembolism prophylaxis with low molecular-weight heparin.


Experimental: Phase I dose level 2
Dose level two consists of 3 study patients receiving 5.000 adoptive SARS-CoV-2 specific T cells (IMP) per kg BW. If the fourth patient does not experience a DLT associated with the dose level two within 28 days, the fifth and sixth patient will receive 5.000 adoptive SARS-CoV-2 specific T cells per kg BW.
Drug: IMP 5,000 plus SoC

Intravenous administration of 5,000 adoptive SARS-CoV-2 specific T cells (IMP) per kg BW.

The adoptive SARS-CoV-2 specific T cells are suspended and formulated in 50 ml of platelet additive solution and will be administered intravenously within 15 min to 30 min.

All study patients at WHO Ordinal Scale ≥ 5 will receive the current SoC for treatment of COVID-19. Currently this is remdesivir (loading dose 200 mg i.v. on day 1, 100 mg maintenance dose day two to five (up to day 10)) - only WHO Ordinal Scale 5, dexamethasone 6 mg once daily p.o. or i.v. up to day 10 and a subcutaneous thromboembolism prophylaxis with low molecular-weight heparin.


Experimental: Phase II SoC plus IMP at the RP2D
Phase II SoC plus IMP at the RP2D consists of 26 patients treated with SoC plus adoptive SARS-CoV-2-specific T cells at the RP2D (Recommended Phase II Dose).
Drug: IMP RP2D plus SoC

Intravenous administration adoptive SARS-CoV-2 specific T cells (IMP) at Recommended Phase II Dose (RP2D).

The adoptive SARS-CoV-2 specific T cells are suspended and formulated in 50 ml of platelet additive solution and will be administered intravenously within 15 min to 30 min.


Active Comparator: Phase II SoC
Phase II SoC consists of 13 patients treated with SoC.
Drug: SoC

Patients will receive the current SoC for treatment of COVID-19.

Currently this is remdesivir (loading dose 200 mg i.v. on day 1, 100 mg maintenance dose day two to five (up to day 10)) - only WHO Ordinal Scale 5, dexamethasone 6 mg once daily p.o. or i.v. up to day 10 and a subcutaneous thromboembolism prophylaxis with low molecular-weight heparin.





Primary Outcome Measures :
  1. Phase I: Dose-limiting toxicities [ Time Frame: 28 days ]
    Dose-limiting toxicities until Day 28 after infusion of SARS-CoV-2- specific T cells

  2. Phase II: [ Time Frame: 28 days ]
    AUC of the course defined by the WHO ordinal scale for COVID-19


Secondary Outcome Measures :
  1. Safety outcome measures [ Time Frame: 3 Month ]
    The rate and severity of adverse events after infusion of SARS-CoV-2 specific T cells during the trial

  2. Acute graft- vs. -host disease [ Time Frame: 100 days after randomization ]
    Clinical manifestations of acute graft- vs. -host disease at day 100 after randomization



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 years or above
  • Written informed consent from the trial subject has been obtained
  • Willing to follow contraception guidelines
  • Tested positive for SARS-CoV-2 by PCR <72 hours after swab
  • WHO score 5 OR
  • WHO score 4 with at least one additional risk factor for disease progression
  • Acceptable risk factors are:

    • Radiographically proven lung infiltrates
    • Immunosuppression either by malignant disease or it's treatment, or other underlying diseases leading to immunodeficiency or underlying diseases that require treatment resulting in immunosuppression
    • Immunosuppressive drugs for example 6mg dexamethasone per os or intravenous 1x/d (SoC) and steroids at a prednisolone equivalent of <1 mg/kg BW) are allowed
    • Autologous transplant during the past 3 months
    • Allogeneic transplant during the past year or ongoing immunosuppression or chronic Graft-versus-Host Disease

Exclusion criteria:

  • Participation in any other clinical trial of an experimental agent treatment for COVID-19
  • COVID-19 WHO ordinal scale ≥6
  • Anticipated life-expectancy <72 hours
  • Expected duration of hospital stay <72 hours
  • Leukocytes <1000/µl or platelets <50.000/µl unless resulting from underlying disease or it's treatment
  • CT pneumonia score ≥13 [50]
  • Any other Steroids ≥ 1mg/kg Prednisolone-equivalent/kg BW, besides 6mg Dexamethasone i.v. or p.o. 1x/d (Standard of Care)
  • Pregnant or breast feeding
  • Any serious medical condition or abnormality of clinical laboratory tests that, in the Investigator's judgment, precludes the subject's safe participation in and completion of the study
  • Failure to use highly-effective contraceptive methods. The following contraceptive methods with a Pearl Index lower than 1% are regarded as highly-effective:

    • Oral hormonal contraception ('pill')
    • Dermal hormonal contraception
    • Vaginal hormonal contraception (NuvaRing®)
    • Contraceptive plaster
    • Long-acting injectable contraceptives
    • Implants that release progesterone (Implanon®)
    • Tubal ligation (female sterilization)
    • Intrauterine devices that release hormones (hormone spiral)
    • Double barrier methods This means that the following are not regarded as safe: condom plus spermicide, simple barrier methods (vaginal pessaries, condom, female condoms), copper spirals, the rhythm method, basal temperature method, and the withdrawal method (coitus interruptus).
  • Persons with any kind of dependency on the principal investigator or employed by the sponsor or principal investigator
  • Legally incapacitated persons
  • Persons held in an institution by legal or official order

[not yet final]


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04762186


Contacts
Layout table for location contacts
Contact: Philipp Köhler, Dr. +49-221-478-85523 philipp.koehler@uk-koeln.de
Contact: Oliver A. Cornely, Prof. +49-221-478-85523 oliver.cornely@uk-koeln.de

Locations
Layout table for location information
Germany
Department I for Internal Medicine University Hospital of Cologne
Cologne, NRW, Germany, 50937
Contact: Philipp Köhler, Dr.    +49-221-478-85523    philipp.koehler@uk-koeln.de   
Contact: Oliver A. Cornely, Prof.    +49-221-478-85523    oliver.cornely@uk-koeln.de   
Principal Investigator: Philipp Köhler, Dr.         
Sub-Investigator: Oliver A. Cornely, Prof.         
Sponsors and Collaborators
Universitätsklinikum Köln
ZKS Köln
MMH Institute for Transfusion Medicine
Miltenyi Biomedicine GmbH
Investigators
Layout table for investigator information
Principal Investigator: Philipp Köhler, Dr. Department I for Internal Medicine University Hospital of Cologne
Layout table for additonal information
Responsible Party: Universitätsklinikum Köln
ClinicalTrials.gov Identifier: NCT04762186    
Other Study ID Numbers: Uni-Koeln-4480
First Posted: February 21, 2021    Key Record Dates
Last Update Posted: February 21, 2021
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Universitätsklinikum Köln:
COVID-19
T-Cell
SARS-CoV-2
Infusion
Adoptive
Allogeneic